Toggle Mobile Navigation

Archive for the ‘Pharmaceutical’ Category

Top 10 Pharma R&D Budgets

Since drug pricing was a noted talking point of the 2016 presidential election, it might not come as a surprise that R&D budgets in the pharmaceutical industry have seen big cuts as a result. And while this comes across as a negative, reduced spending on pharma R&D – though resulting in staff cuts, restructured operations, and more – actually resulted in positive percentage terms in sales. Luckily for us, FierceBiotech has made this information easy to understand in a recently published content report.

R&D spending varied from company to company, but overall,…

READ MORE


Senate Confirms New Head of FDA: Two-Time ExL Speaker Dr. Scott Gottlieb

ExL Events would like to congratulate our speaker alumnus Dr. Scott Gottlieb for the recent United States Senate confirmation, naming him the new Food and Drug Administration commissioner. Dr. Gottlieb was the keynote speaker at ExL’s 2nd Trial Design Innovation Conference and was also a featured speaker at our Private Fee-for-Service event.

President Donald Trump nominated Gottlieb earlier this year, for his previous service as deputy commissioner for the FDA, as well as his experience in the pharmaceutical and health care industries. As the FDA’s newly appointed commissioner, Gottlieb will…

READ MORE


Key Stakeholders Gather This Fall to Discuss Abuse-Deterrent Formulations, Regulations and Policies

Dan Cohen, Chair, ABUSE DETERRENT COALITION
Dan Cohen, Forum Chair, Abuse Deterrent Coalition

This guest blog post is written by Dan Cohen, the Forum Chair of the Abuse Deterrent Coalition and speaker at the 3rd Human Abuse Liability & Abuse-Deterrent Formulations conference, which takes place in Arlington, VA this November 2-3. 

The prominence of Abuse Deterrent Formulations (ADF) in the public policy debate has never been greater.  This fall is no exception as we are now at yet another critical juncture for the ADF sector, with…

READ MORE


live chat software